Clinical Study of Divozilimab in Patients With Systemic Scleroderma

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

152

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

October 1, 2024

Study Completion Date

February 1, 2027

Conditions

Systemic Scleroderma

Interventions

DRUG

Divozilimab

anti CD20 monoclonal antibody

DRUG

Placebo

Trial Locations (3)

Chelyabinsk Regional Clinical hospital, Chelyabinsk

Clinical Rheumatology Hospital №25, Saint Petersburg

North-Western state Medical University named after I.I. Mechnikov, Saint Petersburg